



Universiteit  
Leiden

The Netherlands

## From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice

Tan, Z.

### Citation

Tan, Z. (2026, March 31). *From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice*. Retrieved from <https://hdl.handle.net/1887/4299937>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)


Downloaded from: <https://hdl.handle.net/1887/4299937>

**Note:** To cite this publication please use the final published version (if applicable).



# Section III

Model-informed dose optimization  
of targeted therapies with  
real-world patient data



# Chapter 3

---

## **Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: Towards drug expenses saving regimens**

Zhiyuan Tan, Swantje Völler, Anyue Yin, Amy Rieborn, A. J. Gelderblom, Tom van der Hulle, Catherijne A. J. Knibbe, Dirk Jan A. R. Moes

## ABSTRACT

**Introduction:** Cabozantinib is one of the preferred treatment options in latest meta-static renal cell carcinoma (mRCC) guidelines. Cabozantinib is also associated with high drug expenses irrespective of the used dose because a flat prizing model has been implemented. In addition, concomitant intake with a high-fat meal increases its bioavailability on average by 57%. Combined with the long terminal half-life of cabozantinib (99 hours), this creates possibilities to extend the dosing interval to reduce drug expenses whilst maintaining equivalent exposure.

**Objectives:** The primary objective was to evaluate the population pharmacokinetic (POPPK) model of cabozantinib developed for its registration using real-world patients' therapeutic drug monitoring (TDM) data. The secondary objective was to design, simulate and evaluate alternative dose regimens with the aim to reduce drug expenses whilst maintaining comparable exposure.

**Methods:** Retrospective TDM data from mRCC patients treated with cabozantinib were obtained. The data were evaluated using the published FDA cabozantinib POPPK model, a two-compartment disposition model with a dual (fast and slow) lagged first-order absorption process derived from FDA registration documents, as a basis. Subsequently, simulations of alternative drug expenses saving regimens were evaluated.

**Results:** 27 mRCC patients with 75 pharmacokinetic observations were included. Patients were treated for a median of 75 days with a median dose of 40 mg. Model evaluation results showed that the cabozantinib TDM concentrations were adequately predicted by the published FDA cabozantinib POPPK model, except for a slightly higher CL of 3.11 L/h compared to the reported value (2.23 L/h). The simulation study indicated that an alternative dose regimen that consists of taking 60 mg of cabozantinib for 2 days and then skipping one day results in comparable average exposure when compared with 40 mg daily dose, both without food interaction, while saving 33.3% of the total drug expenses per month. The food effect of a high-fat meal was also taken into account when simulating other alternative dose regimens: 40 mg every 72 h combined with high-fat meal resulted in comparable exposure when compared with 20 mg QD fasted while saving 66.7% in drug expenses.

**Conclusions:** In this study, the FDA cabozantinib POPPK model resulted in adequate prediction of real-world cabozantinib pharmacokinetic data. Alternative dosing regimens with and without using known food interactions were proposed which resulted in potential strategies to significantly reduce cabozantinib drug expenses.

## 1. INTRODUCTION

Renal cell carcinoma (RCC) is one of the prevalent cancer types in Europe. Up to 30% of patients diagnosed with RCC present themselves with synchronous metastases, and recurrence is seen in 30% of patients after complete resection of the primary tumor.<sup>1</sup> The 5-year survival of early-stage RCC is 93%, while metastatic RCC (mRCC) patients have dismal 5-year survival rates of approximately 12%. The therapeutic options for the treatment of metastatic renal cell carcinoma (mRCC) have significantly expanded in recent years, encompassing a diverse range of multi-targeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and mammalian target of rapamycin (mTOR) inhibitors.<sup>2</sup> To date, the dual inhibitor of VEGF receptor and MET proto-oncogene (MET) cabozantinib could improve progression free survival (PFS)/overall survival, and has been proven to be effective as single-agent therapy in patients that were previously treated with VEGF-targeted therapy.<sup>3</sup> In addition, cabozantinib significantly improved median PFS (HR 0.58) and OS (HR 0.66) when compared with everolimus in previously treated mRCC patients.<sup>4</sup> In the newest guidelines,<sup>5,6</sup> cabozantinib is recommended as one of the preferred therapy for mRCC patients with all risk stratifications.

Cabozantinib is approved for mRCC patients at an initial oral daily dose (QD) of 60 mg or 40 mg combined with nivolumab. The approved dose is supported by several population pharmacokinetics (POPPK)/pharmacodynamics (PD) studies with data from clinical trials.<sup>7-10</sup> Exposure-response analysis in the registration file regarding progression free survival (PFS), objective response rate (ORR) and tumor growth inhibition showed that the average exposure of standard dosing with 60 mg had better outcomes while compared with 40 mg and 20 mg doses. However, the real-world tolerability of cabozantinib is quite different from the clinical trials. Previous research<sup>11</sup> by members of our group showed that 77.8% of patients cannot tolerate the labeled 60 mg once daily (QD) dose, which is similar to the findings in the registration study (79% dose reduction).<sup>12</sup> The median best tolerated dose was 40 mg QD. In this report, no clear relationship between increased cabozantinib exposure and improved PFS was observed. Average cabozantinib exposure ( $C_{avg,ss}$ , 572 ng/mL) was below the previously proposed target ( $C_{avg,ss}$  in clinical trials for 40 mg QD dosing, 750 ng/mL<sup>13</sup>) in 83% of patients. Another group<sup>14</sup> demonstrated a threshold of trough concentrations ( $C_{trough}$ ) of 536.8 ng/mL for efficacy and of 617.7 ng/mL for toxicity. Recently Benoit et al.<sup>15</sup> observed even a lower efficacy target of  $C_{trough} > 336$  ng/mL regarding PFS, but was not statistically associated with longer OS. To conclude, tolerability issues seem to reduce the maximum tolerated dose to 40 mg in the large majority of patients without compromising its

efficacy. There is only limited pharmacokinetic information in real world patient data that can be viewed as first step towards characterization of exposure-response of cabozantinib in real world patient data.

Currently, three POPPK models for cabozantinib have been published. Two POPPK models of cabozantinib<sup>8,10</sup> included both healthy volunteers and patients with different tumor types. Another model, based on mRCC patients only, was depicted in the FDA registration file (now referred to as the FDA cabozantinib POPPK model).<sup>13</sup> The POPPK of cabozantinib was, in all cases, described with a dual absorption model with linear elimination process.<sup>8,10,13</sup> Single doses cabozantinib showed dose-proportional increases in mean plasma cabozantinib concentrations. It is worth noting that cabozantinib exhibits an extremely long terminal half-life ( $t_{1/2}$ ), around 99 hours, which leads to a negligible difference in cabozantinib exposure when extending the dosing interval.

A barrier for reimbursement of cabozantinib by healthcare insurance is the high drug expenses, regardless of monotherapy or combined with immunotherapy. Cabozantinib drug expenses are estimated to be €6,200 per patient per month in Europe and a flat pricing model is applicable for all available strengths (20 mg tablet, 40 mg tablet and 60 mg tablet share exactly the same price and therefore have a different price per mg). Nevertheless, several studies on cost-effectiveness<sup>16,17</sup> have found that cabozantinib was more effective than treatment with axitinib or everolimus in mRCC second line treatment but was associated with higher total drug expenses. Previously, high-fat meals proved to increase the cabozantinib exposure by about 57% on average,<sup>18</sup> which represents a dose intensity of 20 mg (fasted) versus 31 mg (non-fasted). Combined with its long terminal half-life this opens the way for potential drug expenses saving regimens while maintaining adequate efficacy, like investigators showed in the DIET study, where 25% of pazopanib expenses could be saved with lower doses taken together with food.<sup>19,20</sup>

The primary objective of this study was to evaluate the predictive value of the POPPK model of cabozantinib used for its registration using real-world patients' therapeutic drug monitoring (TDM) data. The secondary objective was to design, simulate and evaluate alternative dose regimens (equivalent average exposure in steady state within a 3-day interval) with the aim to reduce drug expenses (total expense within a month) using the known drug-high fat meal interaction.



## 2. METHODS

### 2.1. General study design

First, included patients' clinical data were retrieved and a model evaluation with the previous published FDA cabozantinib POPPK model from the registration documents<sup>13</sup> was performed. Subsequently, less complex models were explored and a final POPPK model was established. Based on the final POPPK model, several simulation scenarios were performed with the best tolerated dose (40 mg QD) defined in our previous research<sup>11</sup> to find the regimen with the least drug expenses without significantly reducing  $C_{avg,ss}$  or AUC.

### 2.2. Patients and data

This study was a, single-center retrospective data analysis study of mRCC patients treated with cabozantinib between August 2018 and December 2021 at the Department of Oncology, Leiden University Medical Center (LUMC). Patients with at least one routinely planned TDM observation were included. Demographic (age, weight, height, sex) and laboratory data (liver and renal functions) at start of cabozantinib treatment were retrieved from the electronic health records. Creatine clearance (CrCL) was calculated with CKD-EPI equation expressed as mL/min/1.73 m<sup>2</sup>, which is normalized to a body surface area of 1.73 m<sup>2</sup>.<sup>21</sup> For cabozantinib treatment, information on the start/finish date and time, dose adjustments, dose interruptions, and reason of discontinuation or adjustment, TDM sample time and results were also collected.

This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the Institution Review Board (IRB) at Scientific Committee of Clinical Oncology, Medical Ethics Review Committee Leiden/Den Haag/Delft. As data from routine care was used, a waiver was granted for the requirement of informed consent by IRB.


### 2.3. Bioanalytics of cabozantinib samples

A previously described sensitive and selective ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay was used to determine total cabozantinib concentrations in plasma. The method was validated for cabozantinib in the range 10–4000 ng/mL.<sup>22</sup>

## 2.4. Cabozantinib pharmacokinetic modeling

### 2.4.1. Description of the prior POPPK model

Details on the previously developed population pharmacokinetic model, including the population, development and evaluation are provided in the FDA registration file of cabozantinib for the mRCC indication.<sup>13</sup> In short, the study was based on rich clinical pharmacokinetic data from one Phase I study and one Phase III study of 63 healthy subjects and 325 mRCC patients treated with cabozantinib. A two-compartment disposition model with dual (fast and slow) lagged first-order absorption processes adequately characterized the concentration-time profile of cabozantinib in the above population, which was also depicted in Figure 3.1. Covariates that included in the FDA cabozantinib POPPK model were female gender (21% lower CL/F) and Asian race (27% lower CL/F). This model is referred to as the “FDA cabozantinib POPPK model” in this article.



**Figure 3.1.** Schematic representation of the FDA cabozantinib POPPK model for cabozantinib [13] (Ka1, constant absorption rate from depot 1; Ka2, constant absorption rate from depot 2; ALAG1, lag time of depot 1; ALAG2, lag time of depot 2; CL/F, apparent plasma clearance; Q/F, apparent distribution rate constant between compartments).

### 2.4.2. External model evaluation of the FDA cabozantinib POPPK model using TDM data

The obtained pharmacokinetic data were initially evaluated using the FDA cabozantinib POPPK model. To this end, all parameters' values were fixed to the values described in the registration file.<sup>13</sup> Due to the lack of ethnicity data in the current dataset, it was assumed that all patients were Caucasians since roughly 90% of the population in our University Medical Center is Caucasian. The other covariate, i.e. sex on CL/F, in the FDA cabozantinib POPPK model, were maintained in the model.

### 2.4.3. Further model development

On the basis of the FDA cabozantinib POPPK model, the model was adjusted where needed as follows. (1) Simplification of model structure, which included the possibility of removal of dose-dependent Ka or correlation of random effects. (2) Re-estimating PK

parameters, which included CL/F, inter-individual variability (IIV) of CL/F and residual error. (3) Due to the limited sample size of the real-world dataset, new covariates exploration was skipped and covariates in the FDA cabozantinib POPPK model were maintained.

#### 2.4.4. Model evaluation

##### 2.4.4.1. External evaluation criteria

Individual predicted (IPRED) and observed concentrations (DV) over time, population predicted (PRED) and observed concentrations over time were plotted for each individual for evaluation of the FDA cabozantinib POPPK model fit. Goodness of fit (GOF) plots including IPRED vs. DV, PRED vs. DV, conditional weighted residual error (CWRES, which is the weighted difference between the model prediction based on estimation approximation and the data<sup>23</sup>) vs. PRED and CWRES vs. time after last dose (TAD), were also used to evaluate the performance of the FDA cabozantinib POPPK model.

Apart from the GOF plots, several model accuracy measurements assisted the evaluation. These measurements included mean absolute error (MAE), mean absolute percentage error (MAPE), mean square error (MSE) and Root mean square error (RMSE). The equations are shown below (Eq. 3.1–Eq. 3.4), where  $Obs_i$  represent the individual observation,  $IPRED_i$  represents the individual model prediction,  $n$  represents the number of observations/predictions.

$$MAE = \frac{1}{n} \sum (|Obs_i - IPRED_i|) \quad (\text{Eq. 3.1})$$

$$MAPE = \frac{1}{n} \sum (|Obs_i - IPRED_i|) / Obs_i \quad (\text{Eq. 3.2})$$

$$MSE = \frac{1}{n} \sum_{i=1}^n (Obs_i - IPRED_i)^2 \quad (\text{Eq. 3.3})$$

$$RMSE = \frac{1}{n} \sqrt{\sum_{i=1}^n (Obs_i - IPRED_i)^2} \quad (\text{Eq. 3.4})$$

##### 2.4.4.2. Final model evaluation criteria


Visual evaluation methods (GOF plots) were applied to evaluate the performance. The precision of the PK parameter estimates was expressed as relative standard error (RSE, %) and confidence intervals (CI) of the estimated parameter(s). The RSE were directly computed by NONMEM, and a value < 30% for fixed effects and < 50% for random effects were considered acceptable.<sup>24</sup> Bootstrap and normalized prediction distribution

errors (NPDE) were also performed to evaluate the stability and predictive ability of the model for internal model validation procedures.<sup>25,26</sup> For bootstrap, 1000 replicates datasets were generated by resampling from the original dataset. Median parameter values and the 2.5th – 97.5th percentile from bootstrap estimates were compared with the final model estimates.

## 2.5. Simulations

Simulations to evaluate drug expenses saving regimens were divided into two steps. The first step was to compare the exposure of drug expenses saving regimens in fasted state. The second step was to compare regimens in fed state (high fat meal) with the current recommended daily dose in fasted state.

In previous real-world studies,<sup>11,14,15</sup> the 40 mg QD regimen was defined as best tolerated regimen, which was also used as standard regimen in the simulation part. Based on the final developed model, multiple alternative dosing regimens, with/without high-fat meals, were simulated in order to identify regimens that provide comparable drug exposure as dosing with 40 mg QD but with less drug expenses. To simulate the impact of high-fat meals, it was assumed that the bioavailability of the drug will increase by 50% when taking together with high-fat meals. This is based on a previous Phase I food effect study.<sup>18</sup> The study showed that when cabozantinib capsule was administered with a high fat, high calorie meal in healthy subjects, the maximum concentration ( $C_{max}$ ) and area under the curve (AUC) values ( $AUC_{0-t}$  and  $AUC_{0-inf}$ ) were increased by 41% and 57%, respectively.<sup>18</sup> The detailed simulated regimens were depicted in Figure 3.2.



**Figure 3.2.** Diagram of the simulated regimens. q72h, dosing every 72 hours.

Assessed PK parameters including trough concentration in steady state ( $C_{\min,ss}$ ),  $C_{\max}$  at steady state ( $C_{\max,ss}$ ), average concentration at steady state ( $C_{\text{avg},ss}$ ), area under the concentration-time curve over 72-hour dosing interval ( $AUC_{ss,72h}$ ).  $AUC_{ss,72}$  was derived by adding an AUC compartment in NONMEM control stream. The criteria of bioequivalence of narrow therapeutic index (NTI)<sup>27</sup> drug, which is within 90–111% of assessed PK parameters, was adopted to evaluate these proposed alternative regimens.

## 2.6. Software

Population pharmacokinetic modelling and simulations were performed with the non-linear mixed-effects modelling software NONMEM® version 7.4.4 (Icon Development Solutions, Ellicott City, MD, USA), using Perl-speaks-NONMEM (PsN) Toolkit 4.8.1 and Pirana 2.9.7 as the modelling interface. First-order conditional estimation with interaction (FOCE-I) method was used throughout. Data handling, visualization and statistics were performed in R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).

## 3. RESULTS

### 3.1. Patients

27 patients with 75 observations were included in this study. Patients' characteristics and dosing information are summarized in Table 3.1. The mean age of included patients was 65 years old, and 70% was male. Mean baseline body mass index (BMI) was 24.7 kg/m<sup>2</sup>, mean baseline CrCL was 70 mL/min and mean baseline alanine aminotransferase (ALAT) was 46 U/L. The patients that provided the data for the development of the FDA cabozantinib POPPK model (registration file) originated from one Phase I study (n = 63, healthy volunteers) and one Phase III study (n = 318, mRCC patients). When compared with the patients included in this study (Supplemental Table S3.1), no obvious difference was observed. Concentration versus TAD profiles is shown in Supplemental Figure S3.1. Most samples were obtained under 40 mg QD and 60 mg QD dosing and extensive variability was observed among all dose levels. Median TAD was 25.30 h (1.25–267.15 h) and 48% observations were trough samples and the mean of trough samples were 594.5 ng/mL with a range 308–1134 ng/mL. Steady state was not assumed for the included patients. All administered doses were added to the dataset (for that we used the ADDL and II columns in the NONMEM dataset).

**Table 3.1.** Summary of included patients

	N (%)	Mean (range)
<b>Patients' characteristics</b>		
Total number of patients	27	
Male	19 (70.3%)	
Female	8 (29.7%)	
Age (years)		65 (39–85)
Height (cm)		178 (160–196)
Weight (kg)		78 (49–105)
BMI (kg/m <sup>2</sup> )		25 (18–32)
ALAT (U/L)		46 (14–202)
ASAT (U/L)		51 (14–449)
γ-GT (U/L)		57 (11–563)
Bil (μmol/L)		8 (3–21)
Cr (μmol/L)		96 (50–183)
CrCL (mL/min)		70 (31–121)
<b>Disease characteristics</b>		
WHO performance score		
0	9 (33.3%)	
1	11 (40.7%)	
> 1	7 (26.0%)	
Previous systemic therapy*		
Sunitinib	4 (11.4%)	
Pazopanib	15 (42.9%)	
Nivolumab (± Ipilimumab)	12 (34.3%)	
Everolimus	1 (2.9%)	
No previous system therapy	3 (8.5%)	
Prognosis group		
Favorable	2 (7.4%)	
Intermediate	17 (63.0%)	
Poor	5 (18.5%)	
Unknown	3 (11.1%)	
<b>Cabozantinib dosing</b>		
Cabozantinib dose (mg, QD)		40 (20–60)
Cabozantinib start dose (mg, QD)	20 mg (4, 15%) 40 mg (10, 37%) 60 mg (13, 48%)	
Cabozantinib last dose (mg, QD)	20 mg (5, 19%) 40 mg (16, 60%) 60 mg (6, 21%)	
Cabozantinib treatment days (days)		75 (11–552)
<b>Pharmacokinetic data</b>		
Total number of observations	75	
Total number of trough concentrations	36(48%)	
Number of observations per patient		2 (1–10)
Observed cabozantinib concentration (ng/mL)		603 (135–1471)
Trough cabozantinib concentration (ng/mL)		632 (308–1134)

ASAT, aspartaat aminotransferase; γ-GT, gamma-glutamyltransferase; Bil, Bilirubin; Cr, creatinine.

\* One patient may have several previous system therapies.

### 3.2. External model evaluation of the FDA cabozantinib POPPK model

The model control stream of the FDA Cabozantinib POPPK model was reproduced and is presented in the Supplementary document. Only IIV of fast absorption fraction (IIV\_F1) was decreased from 0.385 to 0.05. It was first set to the value of FDA registration file of 0.385. But the further model optimization steps will be terminated due to negative F1 fraction and impossible to continue based on this value. So we decrease the variance and set to a 20% variation of F1 in both POSTHOC and following final model development. The diagnostic plots are shown in Supplemental Figure S3.2. IPRED versus DV plot indicated acceptable fit with an unbiased loess regression line, while PRED versus DV plot suggested a systematic overestimation of those given 60 mg QD dose. No deviation was observed from the CWRES versus PRED and CWRES versus TAD plots, which indicated no potential misspecification of the model. Further model adjustment was needed to improve PRED to fit for the real-world population.

### 3.3. Further model development


#### 3.3.1. Estimating parameters of the cabozantinib POPPK model

Among the explored models (Supplementary Table S3.2 and Figure S3.3), estimating CL/F and residual error while keeping the other parameters at the original values led to a significantly improved PRED versus DV (Figure 3.3) and lowered OFV by 23. Estimating Vc/F and/or IIV on CL/F, as well as removing IIV correlation of CL/F and Vc/F, did not further improve the model fit. Thus, the IIV on CL/F was kept at the value of the FDA cabozantinib POPPK model. To summary, the changes of final model were estimating CL/F, residual error and decrease IIV\_F1 to 0.05.

The GOF plots of the model is shown in Figure 3.3. The estimated CL/F was 3.11 L/h with a RSE of 5%, which was higher than reported CL/F of 2.23 L/h in the FDA cabozantinib POPPK model (Table 3.2).

#### 3.3.2. Internal model evaluation of the final model

Bootstrap results indicated a stable estimation of the typical value of CL/F with a median 3.11 (95% CI: 2.73–3.58) L/h, which is same with the NONMEM estimate (3.11 L/h). The plots of NPDE frequency distribution, NPDE distribution versus TAD, and NPDE distribution versus the log value of the concentrations, did not show obvious trends or bias in the predictions by the final model, as shown in Supplemental Figure S3.4. The statistical test of NPDE normality indicated a normal distribution.



**Figure 3.3.** GOF plots of the final model (group by dose level).

**Table 3.2.** Parameter estimations of the model from the registration file and the final model


Parameters	Estimates in the registration file	Estimates of the final POPPK model (RSE%)
<b>CL/F (L/h)</b>	<b>2.23</b>	<b>3.11 (5%)</b>
F1 (/)*	0.675	0.675
Vc/F (L)*	81.5	81.5
Vp/F (L)*	213	213
Q/F (L/h)*	14.2	14.2
Ka1 (/h)*	0.568	0.568
ALAG1 (h)*	0.459	0.459
Ka2 (/h)*	0.102	0.102
ALAG2 (h)*	16.8	16.8
Dose exponent on Ka1*	-0.5	-0.5
Female on CL/F*:#	0.79	0.79
Asian on CL/F*:#	0.73	0.73
$\Omega_{CL}$ *	0.213	0.213
$\Omega_{Vc}$ *	1.06	1.06
$\Omega_{Ka}$ *	0.437	0.437
$\Omega_{F1}$ *	0.385 (decrease to 0.05 in external evaluation)	0.05
$\Omega_{CL:Vc}$ *	0.44	0.44
<b>Residual error</b>	<b>0.254</b>	<b>0.335 (10%)</b>

\* Value fixed to the FDA registration file; # transformed estimates correspond to multiplicative change from the typical PK parameter. F1, fraction in the absorption depot 1; Vp/F, apparent peripheral volume of distribution;  $\Omega_{CL}$ , variance of IIV on CL;  $\Omega_{Vc}$ , variance of IIV on Vc;  $\Omega_{Ka}$ , variance of IIV on Ka;  $\Omega_{F1}$ , variance of IIV on F1.



### 3.4. Simulations with the final model

In the first step for alternative drug expenses saving regimens, two regimens assuming fasted status were compared. As depicted in Figure 3.4(a), 40 mg QD has a stable concentration fluctuation during steady state. 60 mg QD given 2 days with one skip day had a higher peak concentration and lower trough concentration than 40 mg QD (still higher than the reference concentrations), as well as a larger fluctuation than 40 mg QD. For the AUC metrics, 40 mg QD and 60 mg QD given 2 days with one subsequent skip day had comparable exposure  $AUC_{ss,72h}$  (relative difference 0.09%) which is bioequivalent according to the criteria described in 2.5. Based on these metrics, 60 mg QD given 2 days with one subsequent skip day maybe an option for potential drug expense savings.



**Figure 3.4.** (a) Simulations of patients taking 40 mg QD cabozantinib fasted versus taking 60 mg QD 2 days + 1 day skip regimen fasted; (b) Simulations of patients taking 40 mg QD cabozantinib fasted versus taking 40 mg QD 2 days + 1 day skip regimen fed; (c) Simulations of patients taking 20 mg QD cabozantinib fasted versus taking 40 mg q72h fed. Black line: median simulation curve; shaded area: 90% PI.

The second step was performed to utilize the food effect for further reduction of cabozantinib expenses. Patients who had a dose reduction from 60 mg QD to 40 mg QD, may be eligible for a regimen that consists of taking cabozantinib 40 mg QD with high-fat meal for 2 days and skip 1 dose day, which was depicted in Figure 3.4(b) resulting in 33% reduction of expenses. Patients that are on a 20 mg QD regimen due to intolerable effects may be eligible for a regimen that consists of 40 mg combined with a high-fat meal every three days, resulting in 67% reducing of expenses. The difference between 20 mg QD fasted and 40 mg q72h fed was depicted in Figure 3.4(c). It is worth noting that in real clinical settings, patients who taking 20 mg QD always have a lower percentile of CL/F and the simulation plot of Figure 3.4(c) was intended to show the comparison of exposure between standard and drug expense-saving regimens which did not represent the real exposure level of 20 mg QD patients. A summary of the exposure metrics of the 1000 simulations is shown in Table 3.3. Comparable  $C_{\min,ss}$ ,  $AUC_{ss,72h}$  were achieved among all comparison groups, respectively. All regimens had bioequivalent clinical outcome-related exposure metrics  $C_{\text{avg},ss}$  (within 90–111%) compared with standard daily fasted dosing.

**Table 3.3.** Exposure metrics comparison of different alternative dosing regimens compared to reference (Mean  $\pm$  SD)

Exposure parameters (Relative change) [Value]	60 mg QD 2 days		20 mg QD fasted		40 mg q72h fed
	40 mg QD fasted (reference)	+ 1 day skip (fasted)	40 mg QD 2 days + 1 day skip (fed)	(reference)	
$C_{\min,ss}$ (ng/mL) <sup>1</sup>	[529 $\pm$ 254]	<b>-11.65%</b> [469 $\pm$ 245]	<b>-4.73%</b> [504 $\pm$ 258]	[269 $\pm$ 127]	<b>-17.84%</b> [221 $\pm$ 121]
$C_{\max,ss}$ (ng/mL)	[727 $\pm$ 383]	<b>5.2%</b> [765 $\pm$ 354]	<b>12.65%</b> [819 $\pm$ 365]	[387 $\pm$ 201]	<b>51.68%</b> [587 $\pm$ 368]
$AUC_{ss,72h}$ (ng·h/mL) <sup>2</sup>	[34270 $\pm$ 14700]	<b>0.02%</b> [34279 $\pm$ 15046]	<b>7.08%</b> [36697 $\pm$ 15709]	[17534 $\pm$ 7388]	<b>3.16%</b> [18088 $\pm$ 7843]
$C_{\text{avg},ss}$ (ng/mL) <sup>3</sup>	[476]	<b>0.00%</b> [476]	<b>6.76%</b> [510]	[244]	<b>2.87%</b> [251]

<sup>1</sup> The minimum concentration during a 72-hour time interval.

<sup>2</sup> The AUC from 864 h to 935 h (72-hour time interval).

<sup>3</sup> Derived by mean of  $AUC_{ss,72h}/72$ .

## 4. DISCUSSION

Although cabozantinib has been available for approximately 7 years, clinical real-world knowledge of its pharmacokinetics and dynamics is still limited. Furthermore, its use is associated with a high financial burden for society as a whole. To the best of our knowledge, this is the first study to evaluate the FDA cabozantinib POPPK model in a real-world setting. In the first part, the FDA cabozantinib POPPK model<sup>13</sup> in registration file was evaluated with an external real-world mRCC cohort. The evaluation indicated an adequate fit of the FDA cabozantinib POPPK model with the real-world data (Supplemental Figure S3.2), with only some underprediction of 60 mg QD dose. After estimating CL/F while fixing all other parameters, the model fit was improved significantly and qualified for simulation of alternative dose regimens. By using the population approach also non steady state data and randomly sampled plasma concentrations could be included to evaluate the performance of the FDA PK model file. In addition the use of the PK model for evaluation of cost reduction strategies also gives insights in increased peak concentrations and can help to design confirmatory prospective studies. In the simulation part, a drug expenses saving regimen in fasted state was developed. A 33% reduction of drug expenses could be achieved with a dose regimen that consists of 60 mg QD given for two subsequent days followed by one day without cabozantinib, when compared a dose regimen of 40 mg QD fasted, while maintaining equivalent drug exposure ( $AUC_{ss,72h}$ ,  $C_{min,ss}$ ,  $C_{avg,ss}$ ) in steady state. Since average concentration in steady state ( $C_{avg,ss}$ ) is used as exposure parameter in registration trials for outcomes and toxicity<sup>7,9,28</sup> and the proposed alternative regimen had similar target achievement ( $C_{avg,ss}$  relative change < 10%), it is highly likely that both efficacy and toxicity will be comparable according to the bioequivalent criteria for both normal drugs (80–125%) and narrow therapeutic index drugs (90–110%).<sup>27</sup> When taking the food effect into consideration, 40 mg q72h with high-fat meal regimen, could result in a 67% reduction of drug expenses when compared with 20 mg QD fasted ( $AUC_{ss,72h}$  relative change +3.16%).

The estimated CL/F of the final model was 3.11 L/h, which was higher than in the FDA cabozantinib POPPK model (2.23 L/h). Except for the FDA registration file, there were only 2 POPPK models of cabozantinib published<sup>8, 10</sup> until the most recent. The first published cabozantinib POPPK study<sup>8</sup> included data from nine clinical studies (three phase I, two phase II and four phase III) for a total of 8072 cabozantinib concentration records from 1534 subjects. A two-compartment model with first-order elimination and a dual absorption (first-order + zero-order) process adequately described the

observed cabozantinib PK data. The CL/F in this study was 2.478 L/h. While splitting the group by tumor types, CL/F for mRCC patients was 2.2 L/h, which was similar to the FDA cabozantinib POPPK model. Shortly after, an updated integrated POPPK model including hepatocellular carcinoma patients was established, and CL/F was estimated to be 2.48 L/h. One explanation for the different CL/F between trials and real-world study could be that dataset from real-world patients consisted of only mRCC patients while in the clinical trials the model<sup>13</sup> was built based on both healthy volunteers and mRCC patients. In addition, in clinical trials, sampling time and strategies were strictly designed. While in routine clinic care, TDM samples were collected sparsely and randomly around trough concentration, which could affect the results of the model parameters estimation. Another possible reason could be the different demographics of the FDA cabozantinib POPPK model's patients and real-world data, since in the FDA cabozantinib POPPK model, data from both healthy volunteers and included mRCC patients were pooled for analysis and clinical performance status of real-world patients was worse than the patients in registration studies.

Previous published case studies<sup>29</sup> have demonstrated how PK modeling complemented traditional pharmacoeconomic analyses by identifying the impact of specific patient subgroups, dose, dosing schedules, and adherence on cost-effectiveness during clinical development. In this study, a general drug expenses saving regimen (using the drug for 2 days and then skip one day) was proposed with comparable exposure ( $C_{\min,ss}$ ,  $C_{\text{avg},ss}$ ,  $AUC_{ss,72h}$ ) which resulted in reducing directly an amount of €2067 per individual per month. The only concern could be the lower exposure on the skip day when compared with the standard QD dosing (RE: -11.65%). But taking into consideration that cabozantinib has an extremely long elimination half-life (~ 99 h),<sup>3</sup> the effect of this slightly lower exposure on the skip day on the efficacy should be negligible. Moreover,  $C_{\max}$  and  $AUC_{0-inf}$  could be increased by high-fat meal by 40.5% and 57.0%, respectively.<sup>18</sup> Therefore, administration in a fasting state (at least 2 h after and 1 h before a meal) is recommended in the drug label.<sup>3</sup> The simulation results of taking the advantage of food effect showed that an amount of up to €4133 per month per individual could be reduced, with comparable exposure metrics. This simulation attempts to provide a unique opportunity regarding cost-effectiveness from PK/PD consideration,<sup>29</sup> not only during drug development but also in real-world practice. Another reference curve of the 95% percentile simulated exposure of cabozantinib label dose (60 mg QD) was added to the simulation plots (Supplemental Figure S3.5), which indicated potential safety of all proposed alternative regimens.

Another important aspect that should be emphasized is, at least in oncology, the reimbursement is not dependent on the dose only, but also on the indication, clinical activity (improvement) compared to standard-of-care) and market size. In previous similar study ASCEND-8 of ceritinib,<sup>30</sup> a low-fat meal with 450 mg enhanced gastrointestinal (GI) tolerability versus 750 mg fasted in patients with ALK-positive NSCLC while maintaining similar exposure. This study led to the label change of manufacturer eventually. However, the current study result could be used a template for other highly expensive drugs with a flat pricing model. Ideally, the root cause for high drug costs is tackled, but this requires a worldwide fundamental system change. Until then, the alternative treatment regimens as proposed by us can be used to reduce drug expenses associated with cabozantinib treatment.

One could argue that concomitant intake with a high fat meal could be inconvenient for some of the patients, specifically in the morning, leading to reduced adherence. Although cabozantinib in principle could also be taken shortly before dinner, a light breakfast was anticipated to be more convenient for most patients. Therefore, a prospective study investigating the effect of a light-breakfast on the pharmacokinetics of cabozantinib was recently designed and is currently recruiting patients which potentially creates additional options for drug expenses saving regimens (NCT05263245). Concomitant food intake could potentially increase variability in exposure. However, in addition TDM could be implemented to minimize the risk of both under and over-exposure. The costs of a single cabozantinib TDM service (will not exceed 250 euros in total per sample) are much less than the potential savings of a regimen of 60 mg QD for days followed by one day off. In addition, according to a previous study that investigating the cost-effectiveness of another TKI (imatinib) TDM, 7% increase of quality adjusted life year (QALY) was achieved with imatinib TDM than imatinib alone which proved that TDM will not add extra economic burden.<sup>31</sup> Therefore it is likely that TDM in addition to the proposed regimens will be cost efficient. Another concern could be the medication compliance in oncology practice. The proposed complex dose skip with high-fat diet regimens for the targeted therapy would be quite challenging for patients to implement or remember.<sup>29</sup> Using medication boxes could be a relatively easy solution for this. It may require additional written and oral patients' education and counselling information<sup>32</sup> to get optimal adherence.

Our study had some limitations. Due to the retrospective nature of the TDM data some inconsistencies might have occurred in the actual time of the last dose intake. However, this heterogeneity is unavoidable in real-world studies and representative for patients

with mRCC in real clinical practice. The current POPPK modeling and simulation study of cabozantinib is the first study to evaluate the registration POPPK model in routine care. In addition, the observed cabozantinib concentrations were comparable to several previously reported real-world analyses,<sup>14, 21</sup> which all had a median  $C_{\min,ss}$  of around 600 ng/mL. Furthermore, the number of patients in this analysis was relatively small to build a POPPK model by ourselves. Therefore, the published cabozantinib POPPK model was adopted with some modifications. More parameters could be estimated if an increased number of samples become available, as well as the identification of significant covariates. The food effect reference that was used was from the cabozantinib capsule formulation rather than the tablet formulations.<sup>18</sup> The systemic exposure following two formulations are similar, however not bioequivalent.<sup>13</sup> Therefore, evaluation of the proposed drug expense saving regimens with/without food effect in should be performed in future prospective clinical studies.

## **5. CONCLUSION**

In this model-based study with real-world patient data, a POPPK model that was based on patients included in studies for registration of cabozantinib resulted generally in adequate prediction for the real-world cabozantinib TDM data. Alternative dosing regimens and options for increasing exposure utilizing the high-fat meal drug-food interaction were proposed that can drastically reduce cabozantinib drug expenses at similar exposure of dosing regimens that have proven to be effective and tolerable.

## **STATEMENTS AND DECLARATIONS**

### **Conflict of interest**

No disclosures are applicable for this work. None of the other authors have any conflicts to declare.

### **Funding**

The work of Zhiyuan Tan was supported by the China Scholarship Council (202108310028).

### **Availability of data and material**

Data are available from the corresponding author upon reasonable request.

## Ethics approval

This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the Institution Review Board (IRB) at Scientific Committee of the department of Medical Oncology, Medical Ethics Review Committee Leiden/Den Haag/Delft. As retrospective data from routine clinical care were used, a waiver was granted for the requirement of informed consent by the IRB.

## Acknowledgements

The authors would like to appreciate Kaj van Schie for contributing to part of the data collection and Tan Zhang for code review.

## REFERENCES

1. Attalla K, Weng S, Voss MH, Hakimi AA. Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. *The Urologic clinics of North America*. Aug 2020;47(3):293-303. doi:10.1016/j.ucl.2020.04.002
2. Hahn AW, Klaassen Z, Agarwal N, et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *European urology oncology*. Nov 2019;2(6):708-715. doi:10.1016/j.euo.2019.09.002
3. Abdelaziz A, Vaishampayan U. Cabozantinib for the treatment of kidney cancer. *Expert review of anti-cancer therapy*. Jul 2017;17(7):577-584. doi:10.1080/14737140.2017.1344553
4. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *The New England journal of medicine*. Nov 5 2015;373(19):1814-23. doi:10.1056/NEJMoa1510016
5. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Annals of oncology : official journal of the European Society for Medical Oncology*. May 1 2019;30(5):706-720. doi:10.1093/annonc/mdz056
6. NCCN. NCCN Guideline Kidney Cancer V1 2021. 2021.
7. Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. *Cancer chemotherapy and pharmacology*. Jun 2018;81(6):1061-1070. doi:10.1007/s00280-018-3579-7
8. Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. *Cancer chemotherapy and pharmacology*. Jun 2018;81(6):1071-1082. doi:10.1007/s00280-018-3581-0
9. Miles DR, Wada DR, Jumbe NL, Lacy SA, Nguyen LT. Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib. *Anti-cancer drugs*. Apr 2016;27(4):328-41. doi:10.1097/cad.0000000000000330
10. Nguyen L, Chapel S, Tran BD, Lacy S. Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma. *Journal of clinical pharmacology*. Nov 2019;59(11):1551-1561. doi:10.1002/jcph.1467
11. Krens SD, van Erp NP, Groenland SL, et al. Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer. *BMC Cancer*. 2022/03/02 2022;22(1):228. doi:10.1186/s12885-022-09338-1
12. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Jun 1 2016;22(11):2613-7. doi:10.1158/1078-0432.Ccr-15-2643
13. CDER. Clinical pharmacology and biopharmaceutics review(s) of cabometyx. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2016/208692Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm)

14. Carbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. *ESMO open*. Dec 2021;6(6):100312. doi:10.1016/j.esmoop.2021.100312
15. Blanchet B, Xu-Vuillard A, Jouinot A, et al. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care. *British Journal of Cancer*. 2024/01/25 2024;doi:10.1038/s41416-024-02585-y
16. Meng J, Lister J, Vataire AL, Casciano R, Dinet J. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. *Clinicoecon Outcomes Res*. 2018;10:243-250. doi:10.2147/ceor.S159833
17. Sieg M, Hartmann M, Settmacher U, Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. *BMC Gastroenterology*. 2020/04/21 2020;20(1):120. doi:10.1186/s12876-020-01241-y
18. Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. *Journal of clinical pharmacology*. Nov 2015;55(11):1293-302. doi:10.1002/jcph.526
19. Lubberman FJE, Gelderblom H, Hamberg P, et al. The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study). *Clinical pharmacology and therapeutics*. Nov 2019;106(5):1076-1082. doi:10.1002/cpt.1515
20. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR. The effect of food on cyclosporine absorption. *Transplantation*. Aug 1985;40(2):174-6. doi:10.1097/00007890-198508000-00013
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. May 5 2009;150(9):604-12. doi:10.7326/0003-4819-150-9-200905050-00006
22. Krens SD, van der Meulen E, Jansman FGA, Burger DM, van Erp NP. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. *Biomedical chromatography : BMC*. Mar 2020;34(3):e4758. doi:10.1002/bmc.4758
23. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. *Pharmaceutical research*. Dec 2007;24(12):2187-97. doi:10.1007/s11095-007-9361-x
24. Alvarez JC, Moine P, Davido B, et al. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. *European Journal of Clinical Pharmacology*. 2021/03/01 2021;77(3):389-397. doi:10.1007/s00228-020-03020-w
25. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. *Comput Methods Programs Biomed*. May 2008;90(2):154-66. doi:10.1016/j.cmpb.2007.12.002
26. Thai HT, Mentré F, Holford NH, Veyrat-Follet C, Comets E. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. *J Pharmacokinet Pharmacodyn*. Feb 2014;41(1):15-33. doi:10.1007/s10928-013-9343-z
27. Jiang W, Makhlouf F, Schuirmann DJ, et al. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion. *Aaps j*. Jul 2015;17(4):891-901. doi:10.1208/s12248-015-9753-5
28. Castellano D, Pablo Maroto J, Benzaghoul F, et al. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. *Cancer treatment reviews*. Sep 2020;89:102062. doi:10.1016/j.ctrv.2020.102062
29. Srinivasan M, White A, Chaturvedula A, et al. Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development. *Pharmacoeconomics*. Oct 2020;38(10):1031-1042. doi:10.1007/s40273-020-00944-0
30. Cho BC, Kim D-W, Bearz A, et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology*. 2017/09/01/ 2017;12(9):1357-1367. doi:https://doi.org/10.1016/j.jtho.2017.07.005
31. Conti RM, Padula WV, Becker RV, Salamone S. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. *Journal of managed care & specialty pharmacy*. Aug 2021;27(8):1077-1085. doi:10.18553/jmcp.2021.27.8.1077




32. Felton MA, van Londen GJ, Marcum ZA. Medication adherence to oral cancer therapy: The promising role of the pharmacist. *Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners*. Apr 2016;22(2):378-81. doi:10.1177/1078155214559114

## SUPPLEMENTAL MATERIALS


**Table S3.1.** Comparison of patient's characteristics in the FDA registration trial and real-world cohort

	N (%)	Mean ± SD	Median (range)	Patients in registration file
<b>Patients' characteristics</b>				
Total number of patients	27			318
Male	19 (70.3%)			253 (77%)
Female	8 (29.7%)			77 (23%)
Age (years)		65 ± 11	68 (39–85)	63 (56–68)
Height (cm)		178 ± 8	178 (160–196)	/
Weight (kg)		78 ± 13	79 (49–105)	/
BMI (kg/m <sup>2</sup> )		25 ± 3	24 (18–32)	27.3 (5.3)
ALAT (U/L)		46 ± 28	39 (14–202)	21.3 (15.5)
ASAT (U/L)		51 ± 54	41 (14–449)	/
γ-GT (U/L)		57 ± 76	34 (11–563)	/
Bil (μmol/L)		8 ± 4	7 (2.5–21)	7.6 (3.2)
Cr (μmol/L)		96 ± 28	98 (50–183)	/
CrCL (mL/min)		70 ± 22	65 (31–122)	76.4 (28.3)
<b>Disease characteristics</b>				
<b>Performance score</b>				
0	9 (33.3%)			226 (68%)
1	11 (40.7%)			104 (32%)
> 1	7 (26.0%)			/
<b>Previous systemic therapy*</b>				
Sunitinib	4 (11.4%)			210 (64%)
Pazopanib	15 (42.9%)			144 (44%)
Nivolumab (±Ipilimumab)	12 (34.3%)			17 (5%)
Everolimus	1 (2.9%)			/
No previous system therapy	3 (8.5%)			/
<b>Prognosis group</b>				
Favorable	2 (7.4%)			150 (45%)
Intermediate	17 (63.0%)			139 (42%)
Poor	5 (18.5%)			41 (12%)
Unknown	3 (11.1%)			/
<b>Cabozantinib dosing</b>				
Cabozantinib dose (mg, QD)		/	40 (20–60)	
Cabozantinib treatment days (days)		/	75 (11–552)	
<b>Pharmacokinetic data</b>				
Total number of observations	75			
Total number of trough concentrations	36 (48%)			
Number of observations per patient		/	2 (1–10)	
Observed cabozantinib concentration (ng/mL)		/	603 (135–1471)	
Cabozantinib trough concentration (ng/mL)		/	632 (308–1134)	

ASAT, aspartaat aminotransferase; γ-GT, gamma-glutamyltransferase; Bil, Bilirubin; Cr, creatinine; /, Not applicable. \* One patient may have several previous system therapies.




**Figure S3.1.** Cabozantinib concentration versus time data of included mRCC patients.




**Figure S3.2.** The GOF plots of the external evaluation of the cabozantinib POPPK model (FDA registration file).


**Table S3.2.** Steps of further model development based on the FDA cabozantinib POPPK model

Steps of further model development	dOFV	Remarks
1. External evaluation (RUNa)	/	IIV_F1 (absorption fraction) was reduced to 20% to solve negative F1 value
2. External evaluation 2 (RUNa1)	+0.1	Removal of ETA CL vs V2 correlation, did not improve model fit
3. Estimate CL/F (RUNb)	-15.04 (compared to RUNa)	Based on RUNa
4. Estimate CL/F and residual error (RUNc)	-8.18 (compared to RUNb)	Stable estimation, chosen as final model
5. Estimate CL/F, IIV_CL/F and residual error (RUNd)	-0.001 (compare to RUNc)	Did not improve the model fit
6. Estimate CL/F, Vc/F, IIV_CL/F, IIV_Vc/F and residual error (RUNe)	-11.40 (compare to RUNd)	High RSE (>50%) of IIV_CL/F and IIV_Vc/F

**Figure S3.3.** DV versus PRED comparison during further model development.



**Figure S3.4.** NPDE results of the optimized model.



**Figure S3.5.** (a) Simulation patients taking 40 mg QD cabozantinib fasted versus taking 60 mg QD 2 days + 1 day skip regimen fasted; (b) Simulation patients taking 40 mg QD cabozantinib fasted versus taking 40 mg QD 2 days + 1 day skip regimen fed; (c) Simulation patients taking 20 mg QD cabozantinib fasted versus taking 40 mg q72h fed. Green line was the 95% percentile of 60 mg QD cabozantinib fasted exposure over time.

**NONMEM CONTROL STREAM POSTHOC OF THE FDA CABOZANTINIB POPPK MODEL (FDA model reproduction)**

```
$INPUT ID TAD=DROP TIME SS=DROP II ADDL DV AMT CMT MDV EVID HT AGE SEX BW
ALAT ASAT GammaGT Bil Cr CRCL OCC=DROP DOSEFLAG
$SUBROUTINES ADVAN6 TOL=3
$MODEL
COMP(ABSORP1)
COMP(ABSORP2)
COMP(CENTRAL)
COMP(PERIPH)
COMP(AUC)

$PK
IF(DOSEFLAG.EQ.1) DOS = 20
IF(DOSEFLAG.EQ.2) DOS = 40
IF(DOSEFLAG.EQ.3) DOS = 60
GEND = 1
IF(SEX.EQ.0) GEND= 1- THETA(12)
RACE=1
ALPHA = THETA(13)
TVCL = THETA(1)
TVV2 = THETA(2)
TVV3 = THETA(3)
TVQ = THETA(4)
TVKA1 = THETA(5)
TVALAG1 = THETA(6)
TVKA2 = THETA(7)
TVALAG2 = THETA(8)
TVF1 = THETA(9)
CL = TVCL * EXP(ETA(1)) * GEND * RACE
V2 = TVV2 * EXP(ETA(2))
V3 = TVV3
Q = TVQ
KA1 = TVKA1*EXP(ETA(3)) *EXP(ALPHA*LOG(DOS/60))
ALAG1 = TVALAG1
KA2 = TVKA2
ALAG2 = TVALAG2
F1 = TVF1 *EXP(ETA(4))
F2 = 1-F1
S3=V2/1000

$DES
DADT(1) = -A(1)*KA1
```

$DADT(2) = -A(2)*KA2$   
 $DADT(3) = A(1)*KA1 + A(2)*KA2 + A(4)*Q/V3 - A(3)*Q/V2 - A(3)*CL/V2$   
 $DADT(4) = -A(4)*Q/V3 + A(3)*Q/V2$   
 $DADT(5) = A(3)/V2$

\$ERROR

IPRED=A(3)\*1000/V2

W=SQRT(THETA(10)\*\*2+(THETA(11)\*IPRED)\*\*2)

Y=IPRED+W\*EPS(1)

IRES=DV-IPRED

IWRES=IRES/(W+0.001)

AUC=A(5)

\$THETA

(2.23) FIX ; CL [L/h]

(81.5) FIX ; V2 [L]

(213) FIX ; V3 [L]

(14.2) FIX ; Q [L/h]

(0.568) FIX ; KA1 [h<sup>-1</sup>]

(0.459) FIX ; ALAG1 [h]

(0.102) FIX ; KA2

(16.8) FIX ; ALAG2

(0.675) FIX ; F1

(0.001) FIX ; Add.RE (sd)

(0.254) FIX ; Prop.RE (sd)

(0.21) FIX ; Gender

(-0.5) FIX ; DOSE exponent on Ka

\$OMEGA BLOCK(2)

0.213 FIX ; CL

0.44 1.06 FIX ; V2

\$OMEGA

0.437 FIX ; KA1

0.385 FIX ; F1

\$SIGMA 1 FIX

\$ESTIMATION METHOD=1 INTER NOABORT MAXEVAL=0 PRINT=10 POSTHOC SIG=1

\$COVARIANCE

**NONMEM CONTROL STREAM SIMULATION WITH THE FINAL CABOZANTINIB PK MODEL**

```
$INPUT ID TIME CMT SS=DROP II=DROP AMT DV MDV EVID DOSEFLAG
```

```
$DATA cabosim_20240227.csv IGNORE=#
```

```
$SUBROUTINES ADVAN6 TOL=3
```

```
$MODEL
```

```
COMP(ABSORP1)
```

```
COMP(ABSORP2)
```

```
COMP(CENTRAL)
```

```
COMP(PERIPH)
```

```
COMP(AUC)
```

```
$PK
```

```
IF(DOSEFLAG.EQ.20) DOS = 20
```

```
IF(DOSEFLAG.EQ.40) DOS = 40
```

```
IF(DOSEFLAG.EQ.60) DOS = 60
```

```
GEND = 1
```

```
RACE=1
```

```
ALPHA = THETA(12)
```

```
TVCL = THETA(1)
```

```
TVV2 = THETA(2)
```

```
TVV3 = THETA(3)
```

```
TVQ = THETA(4)
```

```
TVKA1 = THETA(5)
```

```
TVALAG1 = THETA(6)
```

```
TVKA2 = THETA(7)
```

```
TVALAG2 = THETA(8)
```

```
TVF1 = THETA(9)
```

```
CL = TVCL * EXP(ETA(1)) * GEND
```

```
V2 = TVV2 * EXP(ETA(2))
```

```
V3 = TVV3
```

```
Q = TVQ
```

```
KA1 = TVKA1 * EXP(ETA(3)) * EXP(ALPHA * LOG(DOS/60))
```

```
ALAG1 = TVALAG1
```

```
KA2 = TVKA2
```

```
ALAG2 = TVALAG2
```

```
F1 = TVF1 * EXP(ETA(4))
```

```
F2 = 1-F1
```

```
S3=V2/1000
```



\$DES

$$DADT(1) = -A(1)*KA1$$

$$DADT(2) = -A(2)*KA2$$

$$DADT(3) = A(1)*KA1 + A(2)*KA2 + A(4)*Q/V3 - A(3)*Q/V2 - A(3)*CL/V2$$

$$DADT(4) = -A(4)*Q/V3 + A(3)*Q/V2$$

$$DADT(5) = A(3)/V2$$

\$ERROR

$$IPRED=A(3)*1000/V2$$

$$W=\text{SQRT}(\text{THETA}(10)**2+(\text{THETA}(11)*IPRED)**2)$$

$$Y=IPRED+W*EPS(1)$$

$$IRES=DV-IPRED$$

$$IWRES=IRES/(W+0.001)$$

$$AUC=A(5)$$

\$THETA

(3.11) FIX ; CL [L/h]

(81.5) FIX ; V2 [L]

(213) FIX ; V3 [L]

(14.2) FIX ; Q [L/h]

(0.568) FIX ; KA1 [h<sup>-1</sup>]

(0.459) FIX ; ALAG1 [h]

(0.102) FIX ; KA2

(16.8) FIX ; ALAG2

(0.675) FIX ; F1

(0.001) FIX ; Add.RE (sd)

(0.335) FIX ; Prop.RE (sd)

(-0.5) FIX ; DOSE exponent on Ka

\$OMEGA BLOCK(2) FIX

0.213 ; CL

0.44 1.06 ; V2

\$OMEGA

0.437 FIX ; KA1

0.05 FIX ; F1

\$SIGMA 1 FIX

\$SIMULATION (19950705) ONLYSIM SUBPROBLEMS=1000